SVR12 was achieved in 70 % ( 101/145 ) versus 68 % ( 100/146 ) of previous partial responders and 44 % ( 102/234 ) versus 46 % ( 110/238 ) of previous null responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment , respectively .